The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic Neuropathy

NCT02643251 | Completed Phase 2 Results

• 1 other identifier: CLO-291
• Study Type: interventional
• Target: 138
• Locations: 1 country
• Sites: 25

Brief Summary

The study will include three (3) phases: Screening Phase, Treatment Phase, and Follow-up Phase. Subjects who qualify to participate will apply study drug to their feet three times daily and will record their daily pain scores using an interactive voice response system (IVRS) during the Treatment Phase for 12 weeks. Approximately 100 adult subjects will be randomized to receive Clonidine Gel or Clonidine Gel Comparator.

Conditions

Painful Diabetic Neuropathy; Diabetic Neuropathy; Neuropathy

Keywords

Diabetes Mellitus; Pain; Foot Pain; Neuropathy

Outcome Measures

Primary Outcomes (1)

• Change From Baseline to Day 84 (Week 12) in Numeric Pain Rating Scale Score

  The Numeric Pain Rating Scale is a single reading that measures the patients interpretation of their pain on a scale from 0, no pain to 10, worst pain imaginable. The change from baseline can range from -10 to 10. The change from Baseline (averaged over Day -14 to Day -8) to End-of-Treatment (averaged over Days 78 to 84 \[±3 days\]) in the Numeric Pain Rating Scale score assessing the "average pain in the past 24 hours in the painful areas of the feet" averaged over Days 78 to 84 compared to the 7 days at the Baseline Phase (Days -14 to -8). For the primary efficacy endpoint, the mean change in pain intensity from Baseline to Week 12 was analyzed using an analysis of covariance (ANCOVA) model with the Baseline pain intensity score serving as a covariate. The statistical model also included treatment, site, site by treatment interaction, and strata. If the site by treatment interaction term was not significant at the 0.1 level, then it was excluded from the model.

  The change from Baseline (averaged over Day -14 to Day -8) to End-of-Treatment (averaged over Days 78 to 84 [±3 days])

Secondary Outcomes (1)

• Mean Daily Worst Pain Intensity Numeric Pain Rating Scale Scores

  The change from Baseline (worse over Day -14 to Day -8) to End-of-Treatment (worse over Days 78 to 84 [±3 days])

Study Arms (2)

Clonidine Hydrochloride Topical Gel,0.1%

EXPERIMENTAL

Clonidine Hydrochloride Topical Gel,0.1%

Drug: Clonidine Hydrochloride Topical Gel, 0.1%

Clonidine Hydrochloride Gel Comparator

PLACEBO COMPARATOR

Clonidine Hydrochloride Gel Comparator

Drug: Clonidine Hydrochloride Gel Comparator

Interventions

Clonidine Hydrochloride Topical Gel, 0.1% DRUG

Clonidine Gel is supplied as an aqueous gel formulation for topical use.

Also known as: Clonidine Gel

Clonidine Hydrochloride Topical Gel,0.1%

Clonidine Hydrochloride Gel Comparator DRUG

Clonidine Gel Comparator is supplied as an aqueous gel formulation for topical use.

Also known as: Clonidine Gel Comparator

Clonidine Hydrochloride Gel Comparator

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject is fluent in English and has provided written informed consent.
• Subject is an outpatient ≥18 years of age at the time of the Screening Visit.
• Subject has Type 1 or Type 2 diabetes mellitus with a hemoglobin A1C value \< 10% and has been stable on therapy (diet, oral anti-hyperglycemic, and/or insulin) for at least six (6) months prior to the Screening Visit.
• Subject is a male or non-pregnant, non-lactating female. Females must be practicing an acceptable method of birth control or be surgically sterile or postmenopausal (amenorrhea for ≥12 months). A negative pregnancy test at the Screening and Day 1 visits is required for females of child-bearing potential. Double-barrier methods, hormonal contraceptives, and abstinence are acceptable birth control methods for this study.
• Subject has chronic pain attributable to a symmetrical stocking distribution neuropathy in the lower extremities for at least six (6) months. Pain should be clearly localized to the area of neuropathy (feet), and subjects should be able to distinguish the target pain from other painful areas and conditions.
• Subject has an average pain score relevant to the target pain in the feet of ≥4 on an 11 point numerical pain rating scale over the previous 24 hours at the Screening Visit.
• Subject meets a pre-specified, minimum numerical pain rating scale score following capsaicin skin challenge.
• Subject must satisfactorily complete Accurate Pain Reporting and Minimizing Placebo Response Training.
• Subject must have moderate to severe pain during the Screening Run-in Phase.
• Subjects must be 75 to 110% compliant with application of study drug during the Screening Run-in Phase
• Subject has been medically stable for at least 30 days prior to the Screening Visit, and in the opinion of the Investigator, is in otherwise good general health based on medical history, physical examination, electrocardiogram, and laboratory evaluation.

You may not qualify if:

• Subject has neuropathy secondary to non-diabetic causes in the opinion of the Investigator (e.g., vasculitis, familial neuropathy, alcoholism, pernicious anemia, hepatitis, malignancy, chronic inflammatory demyelinating polyneuropathy \[CIDP\], human immunodeficiency virus \[HIV\], medication-induced neuropathy, vitamin B12 deficiency).
• Subject has a significant neurological disorder or condition that might confound assessment of painful diabetic neuropathy (e.g., stroke with distal neurological deficit, mononeuritis multiplex, lumbar radiculopathy).
• Subject has a confounding disorder as determined by the Algorithm for Excluding Disorders that Masquerade as Painful Diabetic Neuropathy.
• Subject has other sustained pain with intensity at or greater than the bilateral neuropathic pain in the feet.
• Subject is using an implanted medical device (e.g., spinal cord stimulator, intrathecal pump, or peripheral nerve stimulator) for treatment of pain.
• Subject is hypotensive with a resting diastolic blood pressure \<60 mm Hg or a systolic blood pressure \<90 mm Hg at the Screening or Day 1 Visit.
• The subject has recent history (within the past 3 months) or current symptoms of orthostatic hypotension.
• Subject has a history of foot or toe amputation or an active foot or toe ulcer.
• Subject has any significant or unstable medical or psychiatric condition that, in the opinion of the Investigator, would interfere with his/her ability to participate in the study.
• Subject has a history of substance abuse disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, within the past year, has current evidence of substance abuse disorder, is receiving medical treatment for drug abuse, or has a positive urine drug screen for a non-prescribed substance of abuse.
• Subject is receiving or has received within 30 days prior to the Screening Visit any prohibited medications or is anticipated to receive after the start of the trial any new prescription medication for their painful diabetic neuropathy. Subjects may be enrolled if stable on therapy for painful diabetic neuropathy.
• Subject has symptomatic or severe coronary insufficiency, clinically significant cardiac conduction disturbances, myocardial infarction (within last 12 months), moderate to severe cerebrovascular disease, or severe chronic obstructive pulmonary disease (COPD).
• Subject has estimated creatinine clearance less than 50 mL/min (Cockcroft Gault) at the Screening Visit.
• Subject has serum alanine transaminase (ALT) or aspartate transaminase (AST) \>3.0 times the upper limit of normal or total bilirubin concentrations \>2.0 times the upper limit of normal at the Screening Visit.
• Subject has received an investigational drug within 30 days prior to the Screening Visit.

Sponsors & Collaborators

• BioDelivery Sciences International: lead

Study Sites (25)

Unknown Facility

Glendale, Arizona, 85308, United States

Location

Unknown Facility

Phoenix, Arizona, 85018, United States

Location

Unknown Facility

Phoenix, Arizona, 85023, United States

Location

Unknown Facility

Anaheim, California, 92801, United States

Location

Unknown Facility

Norco, California, 92860, United States

Location

Unknown Facility

Sacramento, California, 95821, United States

Location

Unknown Facility

Santa Monica, California, 90404, United States

Location

Unknown Facility

Tustin, California, 92780, United States

Location

Unknown Facility

Fort Myers, Florida, 33912, United States

Location

Unknown Facility

Ocala, Florida, 34471, United States

Location

Unknown Facility

Orlando, Florida, 32801, United States

Location

Unknown Facility

Tampa, Florida, 33634, United States

Location

Unknown Facility

West Palm Beach, Florida, 33401, United States

Location

Unknown Facility

Blackfoot, Idaho, 83321, United States

Location

Unknown Facility

Boise, Idaho, 83642, United States

Location

Unknown Facility

Belleville, Illinois, 62220, United States

Location

Unknown Facility

Blue Island, Illinois, 60406, United States

Location

Unknown Facility

Chicago, Illinois, 60616, United States

Location

Unknown Facility

Hazelwood, Missouri, 63042, United States

Location

Unknown Facility

Cleveland, Ohio, 44122, United States

Location

Unknown Facility

Spartanburg, South Carolina, 29303, United States

Location

Unknown Facility

Knoxville, Tennessee, 37909, United States

Location

Unknown Facility

Houston, Texas, 77030, United States

Location

Unknown Facility

San Antonio, Texas, 78218, United States

Location

Unknown Facility

San Antonio, Texas, 78228, United States

Location

MeSH Terms

Conditions

Diabetic Neuropathies; Diabetes Mellitus; Pain

Condition Hierarchy (Ancestors)

Peripheral Nervous System Diseases; Neuromuscular Diseases; Nervous System Diseases; Diabetes Complications; Endocrine System Diseases; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Results Point of Contact

• Title: Tim Warneke
• Organization: BDSI

twarneke@bdsi.com

919-582-0294

Study Officials

• Aziz Shaibani, MD

  Nerve and Muscule Center of Texas

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: GT60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 29, 2015
• First Posted: December 31, 2015
• Study Start: December 1, 2015
• Primary Completion: November 1, 2016
• Study Completion: November 1, 2016
• Last Updated: September 20, 2017
• Results First Posted: August 9, 2017

Record last verified: 2017-08

Locations

US (25)